In what amounts to a significant leap in understanding the interplay between mental and physiological health, recent research at The Ohio State University has discovered a particularly troubling combination for lung cancer patients. The study, recently published in the journal Biopsychosocial Science and Medicine, suggests that patients grappling with both high levels of depression and inflammation at the time of their diagnosis are likely to continuously endure depressive symptoms for consequent months, regardless of receiving innovative treatments.
According to Barbara L. Andersen, professor of psychology at The Ohio State University and the study's corresponding author, it's the combination of the two—depression and inflammation—that seems to notably and negatively intersect. "What this suggests is that there may be an additive effect or perhaps a synergy between inflammation and depression that can lead to worse outcomes with depression," Andersen told Ohio State News.
The study's patient cohort included 182 individuals who were newly diagnosed with advanced Stage IV lung cancer, followed closely with monthly depression screenings over an eight-month period. While the previous research from the same cohort concluded that depression was tied to increased inflammation levels upon diagnosis, this latest work aimed to further unravel how this duo impacts the trajectory of depression after diagnosis. The findings are particularly concerning, given the established link between high levels of depression and poor outcomes in lung cancer patients.
In their methodology, Andersen and her team accounted for a variety of factors that could potentially skew results, like age, race, and socioeconomic status, seemingly to ensure that what they observed wasn't just about depression or inflammation alone. Rather, it was the grim synergy of both that predicted higher, continuing levels of depression. "Those who had only high levels of depression or only high levels of inflammation, or neither of them, showed no changes in depression over time," the Ohio State News article stated.
This research underscores a critical need for a more nuanced management protocol for lung cancer patients—one that doesn't just aggressively tackle the cancer itself, but also the complex intermingled web of emotional and inflammatory conditions that could, as shown, adversely affect a patient's journey to recovery.
